Gastroparesis, a disorder defined by delayed gastric emptying, and characterized by nausea, vomiting, and other chronic debilitating symptoms that improves little over time, remains among the most challenging gastroenterological conditions to treat.1 With increasing recognition of the size of the market and the large unmet need, it is gratifying to note that the pharmacologic industry has started paying attention to addressing this challenge. An example of the latest effort in this regard is presented in the accompanying article by Lembo et al in this issue of Gastroenterology.